OPKO Health, Inc. Purchase AgreementOpko Health, Inc. • January 9th, 2024 • Pharmaceutical preparations • New York
OPKO Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several initial purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representative (the “Representative”), $200,000,000 aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the “Firm Securities”) and, at the option of the Initial Purchasers, up to an additional $30,000,000 aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the “Option Securities”) if and to the extent that the Initial Purchasers shall have determined to exercise the option to purchase such 3.75% Convertible Senior Notes due 2029 granted to the Initial Purchasers in Section 2 hereof. The Firm Securities and the Option Securities are herein referred to as the “Securities.” Subject to the terms of the Indenture (as defined below), the Securities will be convertible into (i) before the Company satisfies the Share Reservation Condition (as herein
CONVERTIBLE NOTE PURCHASE AGREEMENTConvertible Note Purchase Agreement • January 9th, 2024 • Opko Health, Inc. • Pharmaceutical preparations
This CONVERTIBLE NOTE PURCHASE AGREEMENT (this “Agreement”) is made as of January 4, 2024 by and among OPKO Health, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, a “Purchaser” and, together, the “Purchasers”).
